Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1985 Dec;52(6):937–939. doi: 10.1038/bjc.1985.280

Effective prevention of the nephrotoxicity of cis-platin (CDDP) by administration of sodium 2-mercaptoethane-sulfonate (MESNA) in rats.

S R Kempf, S Ivankovic, M Wiessler, D Schmähl
PMCID: PMC1977286  PMID: 3935152

Full text

PDF
937

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brock N., Pohl J., Stekar J., Scheef W. Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention--III. Profile of action of sodium 2-mercaptoethane sulfonate (mesna). Eur J Cancer Clin Oncol. 1982 Dec;18(12):1377–1387. doi: 10.1016/0277-5379(82)90143-2. [DOI] [PubMed] [Google Scholar]
  2. Brock N. The development of mesna for the inhibition of urotoxic side effects of cyclophosphamide, ifosfamide, and other oxazaphosphorine cytostatics. Recent Results Cancer Res. 1980;74:270–278. doi: 10.1007/978-3-642-81488-4_32. [DOI] [PubMed] [Google Scholar]
  3. Campbell A. B., Kalman S. M., Jacobs C. Plasma platinum levels: relationship to cisplatin dose and nephrotoxicity. Cancer Treat Rep. 1983 Feb;67(2):169–172. [PubMed] [Google Scholar]
  4. Choie D. D., Longnecker D. S., del Campo A. A. Acute and chronic cisplatin nephropathy in rats. Lab Invest. 1981 May;44(5):397–402. [PubMed] [Google Scholar]
  5. Goldstein R. S., Mayor G. H. Minireview. The nephrotoxicity of cisplatin. Life Sci. 1983 Feb 14;32(7):685–690. doi: 10.1016/0024-3205(83)90299-0. [DOI] [PubMed] [Google Scholar]
  6. Gonzales-Vitale J. C., Hayes D. M., Cvitkovic E., Sternberg S. S. The renal pathology in clinical trials of cis-platinum (II) diamminedichloride. Cancer. 1977 Apr;39(4):1362–1371. doi: 10.1002/1097-0142(197704)39:4<1362::aid-cncr2820390403>3.0.co;2-n. [DOI] [PubMed] [Google Scholar]
  7. Hayes D. M., Cvitkovic E., Golbey R. B., Scheiner E., Helson L., Krakoff I. H. High dose cis-platinum diammine dichloride: amelioration of renal toxicity by mannitol diuresis. Cancer. 1977 Apr;39(4):1372–1381. doi: 10.1002/1097-0142(197704)39:4<1372::aid-cncr2820390404>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
  8. Kociba R. J., Sleight S. D. Acute toxicologic and pathologic effects of cis-diamminedichloroplatinum (NSC-119875) in the male rat. Cancer Chemother Rep. 1971 Feb;55(1):1–8. [PubMed] [Google Scholar]
  9. Ozols R. F., Corden B. J., Jacob J., Wesley M. N., Ostchega Y., Young R. C. High-dose cisplatin in hypertonic saline. Ann Intern Med. 1984 Jan;100(1):19–24. doi: 10.7326/0003-4819-100-1-19. [DOI] [PubMed] [Google Scholar]
  10. Rosenberg B., VanCamp L., Trosko J. E., Mansour V. H. Platinum compounds: a new class of potent antitumour agents. Nature. 1969 Apr 26;222(5191):385–386. doi: 10.1038/222385a0. [DOI] [PubMed] [Google Scholar]
  11. Rozencweig M., von Hoff D. D., Slavik M., Muggia F. M. Cis-diamminedichloroplatinum (II). A new anticancer drug. Ann Intern Med. 1977 Jun;86(6):803–812. doi: 10.7326/0003-4819-86-6-803. [DOI] [PubMed] [Google Scholar]
  12. Scheef W., Klein H. O., Brock N., Burkert H., Günther U., Hoefer-Janker H., Mitrenga D., Schnitker J., Voigtmann R. Controlled clinical studies with an antidote against the urotoxicity of oxazaphosphorines: preliminary results. Cancer Treat Rep. 1979 Mar;63(3):501–505. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES